Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report) reached a new 52-week high during trading on Tuesday following insider buying activity. The stock traded as high as C$11.42 and last traded at C$11.33, with a volume of 3640 shares traded. The stock had previously closed at C$9.50.
Specifically, Director Jeffrey Hackman bought 15,000 shares of the business’s stock in a transaction that occurred on Monday, May 19th. The stock was purchased at an average cost of C$9.77 per share, with a total value of C$146,580.00.
Fennec Pharmaceuticals Stock Up 18.0%
The business’s 50 day simple moving average is C$8.25 and its 200 day simple moving average is C$8.44. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83. The firm has a market capitalization of C$216.18 million, a PE ratio of -189.90 and a beta of 0.25.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Featured Articles
- Five stocks we like better than Fennec Pharmaceuticals
- Canada Bond Market Holiday: How to Invest and Trade
- Boeing Landed New Deals With China and the Saudis for More Upside
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Hims & Hers Stock Chart Points to Strong Bullish Continuation
- Most Volatile Stocks, What Investors Need to Know
- CrowdStrike’s Rally Faces a Test—Here’s Why That’s Good
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
